Multiple Myeloma Stages
Multiple myeloma is a cancer of plasma cells in the bone marrow, and understanding how it progresses is essential for guiding treatment decisions and setting realistic expectations. Staging provides clinicians and patients with a structured framework that reflects disease severity, helping to tailor therapy and anticipate outcomes.
Key Takeaways
- Multiple myeloma is staged using the International Staging System (ISS) and the Revised ISS (R-ISS), both of which rely on measurable blood markers.
- There are three stages — Stage 1, Stage 2, and Stage 3 — each reflecting increasing disease burden and differing prognostic outlooks.
- R-ISS improves on ISS by incorporating chromosomal abnormalities and lactate dehydrogenase (LDH) levels for a more precise prognosis.
- Median survival varies meaningfully across stages, though advances in therapy continue to extend life expectancy at every stage.
- Staging is a dynamic assessment; a patient’s stage can influence but does not solely determine treatment choices or outcomes.
How Multiple Myeloma Is Staged: ISS and R-ISS Systems
The multiple myeloma staging system most widely used today is the International Staging System (ISS), introduced in 2005 through a landmark analysis by the International Myeloma Working Group (IMWG). The ISS classifies patients into three stages based on two readily measurable serum markers: beta-2 microglobulin (β2M) and serum albumin. These biomarkers reflect both tumor burden and the overall nutritional and immune status of the patient, making them reliable surrogates for disease severity.
Because the original ISS did not account for chromosomal risk or other prognostic variables, the IMWG published the Revised International Staging System (R-ISS) in 2015. The R-ISS adds two critical parameters: cytogenetic abnormalities detected by fluorescence in situ hybridization (FISH) — particularly high-risk features such as del(17p), t(4;14), and t(14;16) — and serum lactate dehydrogenase (LDH) levels. Elevated LDH is associated with high tumor proliferation and poorer outcomes, while certain chromosomal deletions indicate aggressive disease biology. Together, these refinements allow oncologists to distinguish patients within the same ISS stage who may have very different prognoses.
In clinical practice, staging begins at diagnosis and relies on laboratory tests rather than imaging alone. A complete staging workup typically includes serum protein electrophoresis, immunofixation, free light chain assay, a complete blood count, and bone marrow biopsy. Skeletal surveys or whole-body low-dose computed tomography (CT) scans complement laboratory staging by identifying lytic bone lesions. According to data published by the American Cancer Society, multiple myeloma accounts for approximately 10% of all blood cancers diagnosed in the United States, underscoring the importance of standardized staging for such a prevalent malignancy.
ISS Criteria at a Glance
Under the ISS, Stage 1 requires serum β2M below 3.5 mg/L and serum albumin at or above 3.5 g/dL. Stage 3 is defined by serum β2M at or above 5.5 mg/L, regardless of albumin. Stage 2 encompasses all patients who meet neither the Stage 1 nor the Stage 3 criteria. The R-ISS then overlays cytogenetic and LDH data to further stratify each ISS category into low, intermediate, or high risk.
Why the R-ISS Represents a Meaningful Advance
Earlier staging tools could not explain why two patients with identical ISS scores sometimes experienced dramatically different disease courses. By incorporating genomic risk — specifically high-risk chromosomal abnormalities and elevated LDH — the R-ISS captures the underlying biology of the disease more accurately. Clinical studies validating the R-ISS showed that R-ISS Stage 3 patients had a median overall survival of approximately 43 months, compared with more than 83 months for R-ISS Stage 1 patients, illustrating the system’s practical value in predicting outcomes.
Multiple Myeloma Stages 1, 2, and 3: Key Differences
The multiple myeloma stage 1, 2, and 3 differences are rooted in measurable biological markers rather than symptoms alone. At Stage 1, the disease burden is relatively low: β2M is less than 3.5 mg/L, albumin remains preserved, and, under the R-ISS, there are no high-risk chromosomal abnormalities and LDH is within normal range. Patients at this stage often have limited end-organ damage and may have been diagnosed incidentally during routine blood work.
Stage 2 represents an intermediate category. Patients here do not satisfy all Stage 1 criteria but fall short of the more severe thresholds that define Stage 3. This group is heterogeneous — some patients are closer to Stage 1 in their clinical picture, while others approach Stage 3 in disease burden. Under the R-ISS, Stage 2 encompasses a wide range, including ISS Stage 1 or 2 with high-risk cytogenetics, or ISS Stage 3 without high-risk genetics and with normal LDH. This breadth makes Stage 2 the most variable in terms of prognosis.
Stage 3 is characterized by β2M at or above 5.5 mg/L, which signals a substantially higher tumor burden. When combined with high-risk chromosomal abnormalities or elevated LDH under the R-ISS, Stage 3 carries the most guarded prognosis. Patients at this stage are more likely to present with symptomatic bone disease, anemia, renal impairment, or hypercalcemia — the classic CRAB criteria (hyperCalcemia, Renal insufficiency, Anemia, Bone lesions) that define symptomatic myeloma requiring treatment.
| Stage | ISS Criteria | R-ISS Addition | General Disease Burden |
|---|---|---|---|
| Stage 1 | β2M < 3.5 mg/L; Albumin ≥ 3.5 g/dL | No high-risk cytogenetics; normal LDH | Low |
| Stage 2 | Neither Stage 1 nor Stage 3 criteria met | Mixed cytogenetic/LDH risk profiles | Intermediate |
| Stage 3 | β2M ≥ 5.5 mg/L | High-risk cytogenetics and/or elevated LDH | High |
It is worth noting that staging reflects the disease state at a specific point in time. Unlike solid tumor staging, which often incorporates anatomical spread, myeloma staging is entirely biomarker-driven. A patient’s clinical presentation — including the degree of bone involvement or renal function — may not always correlate directly with their assigned stage, which is why oncologists consider staging alongside the full clinical picture when planning therapy.
Disease Progression and Prognosis by Stage
Multiple myeloma disease progression by stage describes the trajectory of the disease as tumor burden increases and normal bone marrow function becomes increasingly compromised. In early-stage disease, the malignant plasma cell clone is smaller, end-organ damage is minimal or absent, and the immune system retains more functional capacity. As the disease advances through Stage 2 and into Stage 3, expanding plasma cell populations suppress normal blood cell production, secrete excess monoclonal protein that can damage the kidneys, and release factors that activate osteoclasts — leading to painful lytic bone lesions and fracture risk.
The life expectancy for each stage of multiple myeloma has improved substantially over the past two decades due to the introduction of novel therapies, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, and, more recently, CAR-T cell therapies. Based on R-ISS validation data, median overall survival for Stage 1 patients exceeded 83 months, Stage 2 patients had a median of approximately 62 months, and Stage 3 patients approximately 43 months. However, these figures represent population-level medians from earlier treatment eras; outcomes with current regimens are generally more favorable across all stages.
Progression from one stage to the next is not inevitable or uniform. Some patients with Stage 1 disease remain stable for years, particularly those initially diagnosed with smoldering myeloma — a precursor state that can precede active disease. Conversely, high-risk cytogenetic features at any stage can accelerate disease course independent of ISS classification. Relapse remains a central challenge: most patients eventually experience disease recurrence after initial treatment, and subsequent lines of therapy are typically required. Monitoring tools such as minimal residual disease (MRD) testing are increasingly used to assess treatment depth and predict relapse risk more precisely than stage alone.
Supportive care also plays a meaningful role in managing disease-related complications at every stage. Bisphosphonates are commonly used to reduce skeletal-related events, while erythropoiesis-stimulating agents or transfusions may address anemia. Renal function is monitored closely, particularly in Stage 3, where paraprotein-induced nephropathy is more prevalent. These interventions do not alter the stage itself but significantly affect quality of life and functional outcomes throughout the disease course.
Frequently Asked Questions
Can multiple myeloma be caught at Stage 1 before symptoms appear?
Yes. Because Stage 1 is defined by laboratory markers rather than symptoms, it can be identified during routine blood tests ordered for unrelated reasons. Elevated serum protein or an abnormal protein electrophoresis finding often prompts further workup. Early-stage detection, while not always requiring immediate treatment, allows for close monitoring and timely intervention before significant end-organ damage occurs. Regular follow-up with a hematologist or oncologist is essential once myeloma or a precursor condition is identified.
Does a higher stage always mean a worse outcome?
Not necessarily. While higher stages are statistically associated with shorter survival at a population level, individual outcomes vary considerably based on factors such as cytogenetic profile, age, overall health, response to initial therapy, and access to newer treatments. Some Stage 3 patients respond exceptionally well to modern regimens, while certain Stage 1 patients with high-risk chromosomal features may follow a more aggressive course. Staging is one prognostic tool among several, not an absolute predictor of an individual patient’s trajectory.
Is staging used to decide when to start treatment?
Stage alone does not always determine when treatment begins. Active myeloma causing CRAB criteria — hypercalcemia, renal impairment, anemia, or bone lesions — requires prompt treatment regardless of stage. Smoldering or asymptomatic myeloma may be monitored without immediate therapy, though clinical trials are exploring early intervention for high-risk smoldering disease. Treatment decisions integrate staging with cytogenetic risk, patient fitness, comorbidities, and shared decision-making between the patient and their oncology team.
